US FDA Accepts Bristol-Myers Squibb’s sBLA for Opdivo (nivolumab) to Include Previously Treated Squamous NSCLC
Lung Cancer, News
The US Food and Drug Administration recently accepted Bristol-Myers Squibb Company’s supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for review as a treatment for previously treated patients with non-squamous (NSQ) non-small cell ... Read more